Mizuho Lifts PT on DexCom (DXCM) to $100 From $95, Keeps an Outperform Rating

DexCom, Inc. (NASDAQ:DXCM) is one of the best strong buy healthcare stocks to buy now. On July 16, Mizuho analyst Anthony Petrone raised the firm’s price target on DexCom, Inc. (NASDAQ:DXCM) to $100 from $95 while keeping an Outperform rating on the shares.

Why DexCom Inc. (DXCM) Soared Last Week

A doctor demonstrating how to use the medical device to a patient with diabetes.

The rating update came with the firm adjusting price targets in the medical devices and diagnostics sector ahead of Q2 2025 earnings. DexCom, Inc. (NASDAQ:DXCM) is set to report its Q2 results on July 30.

DexCom, Inc. (NASDAQ:DXCM) is a medical device company that manufactures continuous glucose monitoring (CGM) systems to allow real-time health management control. Specializing in diabetes care technology, the company helps improve and simplify diabetes management worldwide.

It offers various medical devices and products, including Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE.

While we acknowledge the potential of DXCM to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than DXCM and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.